Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tyler Pond

Physician Assistant Idaho Falls, ID Physician Assistant

NPI 1356844500 CMS profile 10799100

150 N Woodruff Ave, Idaho Falls, ID 83401

Open in the dashboard

General payments

$12,777

261 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tyler Pond of Idaho Falls, ID is reported in the CMS Open Payments database as having received $12,777 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,007 68
2024 General $645 37
2023 General $804 39
2022 General $1,166 63
2021 General $1,156 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Pond
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tyler Pond were reported at $9,007. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tyler Pond Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,156 $132 $37–$438 $132
2022 $1,166 $155 $48–$522 $149
2023 $804 $167 $52–$557 $160
2024 $645 $178 $55–$600 $164
2025 $9,007 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $8,859 65 payments
  2. ITI, Inc. $1,206 53 payments
  3. Vanda Pharmaceuticals Inc. $363 15 payments
  4. Otsuka America Pharmaceutical, Inc. $337 20 payments
  5. Janssen Pharmaceuticals, Inc $327 12 payments
  6. Alkermes, Inc. $317 14 payments
  7. Teva Pharmaceuticals USA, Inc. $289 19 payments
  8. Neurocrine Biosciences, Inc. $177 8 payments
  9. Lundbeck LLC $125 7 payments
  10. Supernus Pharmaceuticals, Inc. $106 7 payments
  11. Other $671 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,750 5 payments
  2. Food and Beverage $5,062 251 payments
  3. Travel and Lodging $901 2 payments
  4. Education $65 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $7,850 15 payments
  2. CAPLYTA Psychiatry $967 43 payments
  3. VRAYLAR Neuroscience $842 47 payments
  4. FANAPT $363 15 payments
  5. SPRAVATO $283 9 payments
  6. CAPLYTA Psychiatry $239 10 payments
  7. LYBALVI Cns $206 6 payments
  8. LYBALVI Cns $190 5 payments
  9. INGREZZA $165 7 payments
  10. LYBALVI Cns $164 3 payments
  11. Other $2,746 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,508

Median for Physician Assistant: 241

Drug cost

$207,029

Median for Physician Assistant: $4,110

Branded share of claims

24.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 34 $48,217
Caplyta Lumateperone Tosylate Brand 23 $38,966
Abilify Maintena Aripiprazole Brand 15 $32,693
Auvelity Dextromethorphan Hbr/Bupropion Brand 32 $28,135
Trintellix Vortioxetine Hydrobromide Brand 36 $19,931
Savella Milnacipran Hcl Brand 12 $5,603
Aripiprazole Generic 63 $4,738
Ramelteon Generic 15 $4,685
Vilazodone Hcl Generic 37 $4,076
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 39 $2,910

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$24,362

Medicare's payments for the services billed

Medicare patients

39

Average age 58

Services billed

378

28 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 72%
High blood pressure 44%
Arthritis 44%
Diabetes 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $163
$163 34 —
CAPLYTA
  • ITI, Inc. $111
$111 23 —
REXULTI
  • Lundbeck LLC $45
  • Otsuka America Pharmaceutical, Inc. $36
$81 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $52
$52 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record